Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001615774-19-002502
Filing Date
2019-02-14
Accepted
2019-02-14 15:25:30
Documents
1
Group Members
VIVO OPPORTUNITY, LLC

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13G/A s116127_sc13ga.htm SC 13G/A 110356
  Complete submission text file 0001615774-19-002502.txt   111944
Mailing Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301
Business Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301 650 688 0822
Vivo Capital VIII, LLC (Filed by) CIK: 0001618789 (see all company filings)

EIN.: 471761992 | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Subject) CIK: 0001641640 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-89113 | Film No.: 19605333
SIC: 2834 Pharmaceutical Preparations